Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

ADC Therapeutics (ADCT) Shares Outstanding (2020 - 2026)

ADC Therapeutics has reported Shares Outstanding over the past 7 years, most recently at $127.2 million for Q1 2026.

  • Quarterly results put Shares Outstanding at $127.2 million for Q1 2026, up 24.97% from a year ago — trailing twelve months through Mar 2026 was $127.2 million (up 24.97% YoY), and the annual figure for FY2025 was $125.7 million, up 23.76%.
  • Shares Outstanding reached $127.2 million in Q1 2026 per ADCT's latest filing, up from $125.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $127.2 million in Q1 2026 and bottomed at $89.0 million in Q1 2023.
  • Median Shares Outstanding over the past 5 years was $99.5 million (2024), compared with a mean of $101.5 million.
  • The largest annual shift saw Shares Outstanding fell 3.66% in 2023 before it rose 24.97% in 2026.
  • Over 5 years, Shares Outstanding stood at $92.4 million in 2022, then dropped by 3.66% to $89.0 million in 2023, then rose by 14.11% to $101.6 million in 2024, then rose by 23.76% to $125.7 million in 2025, then rose by 1.13% to $127.2 million in 2026.
  • Business Quant data shows Shares Outstanding for ADCT at $127.2 million in Q1 2026, $125.7 million in Q4 2025, and $112.6 million in Q3 2025.